Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial.

Skytte MJ, Samkani A, Petersen AD, Thomsen MN, Astrup A, Chabanova E, Frystyk J, Holst JJ, Thomsen HS, Madsbad S, Larsen TM, Haugaard SB, Krarup T.

Diabetologia. 2019 Nov;62(11):2066-2078. doi: 10.1007/s00125-019-4956-4. Epub 2019 Jul 23.

PMID:
31338545
2.

Comparison of refractive predictability and endothelial cell loss in femtosecond laser-assisted cataract surgery and conventional phaco surgery: prospective randomised trial with 6 months of follow-up.

Krarup T, Ejstrup R, Mortensen A, la Cour M, Holm LM.

BMJ Open Ophthalmol. 2019 Mar 1;4(1):e000233. doi: 10.1136/bmjophth-2018-000233. eCollection 2019.

3.

Corrigendum to "Dietary carbohydrate restriction as the first approach in diabetes management: Critical review and evidence base" [Nutrition 31 (2015) 1-13].

Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, Accurso A, Frassetto L, Gower BA, McFarlane SI, Nielsen JV, Krarup T, Saslow L, Roth KS, Vernon MC, Volek JS, Wilshire GB, Dahlqvist A, Sundberg R, Childers A, Morrison K, Manninen AH, Dashti HM, Wood RJ, Wortman J, Worm N.

Nutrition. 2019 Jun;62:213. doi: 10.1016/j.nut.2018.12.002. Epub 2019 Mar 29. No abstract available.

PMID:
30935711
4.

Mechanisms of action of a carbohydrate-reduced, high-protein diet in reducing the risk of postprandial hypoglycemia after Roux-en-Y gastric bypass surgery.

Kandel D, Bojsen-Møller KN, Svane MS, Samkani A, Astrup A, Holst JJ, Madsbad S, Krarup T.

Am J Clin Nutr. 2019 Aug 1;110(2):296-304. doi: 10.1093/ajcn/nqy310.

PMID:
30624666
5.

The acute effects of dietary carbohydrate reduction on postprandial responses of non-esterified fatty acids and triglycerides: a randomized trial.

Samkani A, Skytte MJ, Anholm C, Astrup A, Deacon CF, Holst JJ, Madsbad S, Boston R, Krarup T, Haugaard SB.

Lipids Health Dis. 2018 Dec 27;17(1):295. doi: 10.1186/s12944-018-0953-8.

6.

Acute Effects of Dietary Carbohydrate Restriction on Glycemia, Lipemia and Appetite Regulating Hormones in Normal-Weight to Obese Subjects.

Samkani A, Skytte MJ, Thomsen MN, Astrup A, Deacon CF, Holst JJ, Madsbad S, Rehfeld JF, Krarup T, Haugaard SB.

Nutrients. 2018 Sep 12;10(9). pii: E1285. doi: 10.3390/nu10091285.

7.

The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial.

Nordklint AK, Almdal TP, Vestergaard P, Lundby-Christensen L, Boesgaard TW, Breum L, Gade-Rasmussen B, Sneppen SB, Gluud C, Hemmingsen B, Jensen T, Krarup T, Madsbad S, Mathiesen ER, Perrild H, Tarnow L, Thorsteinsson B, Vestergaard H, Lund SS, Eiken P.

Osteoporos Int. 2018 Nov;29(11):2517-2526. doi: 10.1007/s00198-018-4637-z. Epub 2018 Jul 19.

PMID:
30027438
8.

A carbohydrate-reduced high-protein diet acutely decreases postprandial and diurnal glucose excursions in type 2 diabetes patients.

Samkani A, Skytte MJ, Kandel D, Kjaer S, Astrup A, Deacon CF, Holst JJ, Madsbad S, Rehfeld JF, Haugaard SB, Krarup T.

Br J Nutr. 2018 Apr;119(8):910-917. doi: 10.1017/S0007114518000521.

PMID:
29644957
9.

Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial.

Lundby-Christensen L, Vaag A, Tarnow L, Almdal TP, Lund SS, Wetterslev J, Gluud C, Boesgaard TW, Wiinberg N, Perrild H, Krarup T, Snorgaard O, Gade-Rasmussen B, Thorsteinsson B, Røder M, Mathiesen ER, Jensen T, Vestergaard H, Hedetoft C, Breum L, Duun E, Sneppen SB, Pedersen O, Hemmingsen B, Carstensen B, Madsbad S.

BMJ Open. 2016 Feb 25;6(2):e008377. doi: 10.1136/bmjopen-2015-008377.

10.

Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus-the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial.

Lundby-Christensen L, Tarnow L, Boesgaard TW, Lund SS, Wiinberg N, Perrild H, Krarup T, Snorgaard O, Gade-Rasmussen B, Thorsteinsson B, Røder M, Mathiesen ER, Jensen T, Vestergaard H, Hedetoft C, Breum L, Duun E, Sneppen SB, Pedersen O, Hemmingsen B, Carstensen B, Madsbad S, Gluud C, Wetterslev J, Vaag A, Almdal TP.

BMJ Open. 2016 Feb 25;6(2):e008376. doi: 10.1136/bmjopen-2015-008376.

11.

Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance.

Eriksen M, Jensen DH, Tribler S, Holst JJ, Madsbad S, Krarup T.

Diabetologia. 2015 May;58(5):920-8. doi: 10.1007/s00125-015-3522-y. Epub 2015 Mar 9.

PMID:
25748606
12.

Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base.

Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, Accurso A, Frassetto L, Gower BA, McFarlane SI, Nielsen JV, Krarup T, Saslow L, Roth KS, Vernon MC, Volek JS, Wilshire GB, Dahlqvist A, Sundberg R, Childers A, Morrison K, Manninen AH, Dashti HM, Wood RJ, Wortman J, Worm N.

Nutrition. 2015 Jan;31(1):1-13. doi: 10.1016/j.nut.2014.06.011. Epub 2014 Jul 16. Review. Erratum in: Nutrition. 2019 Jun;62:213.

13.

Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.

Aaboe K, Akram S, Deacon CF, Holst JJ, Madsbad S, Krarup T.

Diabetes Obes Metab. 2015 Jan;17(1):74-81. doi: 10.1111/dom.12395. Epub 2014 Oct 26.

PMID:
25243647
14.

Endothelial cell loss and refractive predictability in femtosecond laser-assisted cataract surgery compared with conventional cataract surgery.

Krarup T, Holm LM, la Cour M, Kjaerbo H.

Acta Ophthalmol. 2014 Nov;92(7):617-22. doi: 10.1111/aos.12406. Epub 2014 Jun 2.

15.

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report.

Knop FK, Lund A, Madsbad S, Holst JJ, Krarup T, Vilsbøll T.

BMC Res Notes. 2014 May 31;7:326. doi: 10.1186/1756-0500-7-326.

16.

Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.

Reaney M, Mathieu C, Ostenson CG, Matthaei S, Krarup T, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M, Guerci B.

Health Qual Life Outcomes. 2013 Dec 26;11:217. doi: 10.1186/1477-7525-11-217.

17.

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.

Mathieu C, Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M.

Diabetes Ther. 2013 Dec;4(2):285-308. doi: 10.1007/s13300-013-0037-8. Epub 2013 Sep 10.

18.

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.

Kiiskinen U, Matthaei S, Reaney M, Mathieu C, Ostenson CG, Krarup T, Theodorakis M, Kiljański J, Salaun-Martin C, Sapin H, Guerci B.

Clinicoecon Outcomes Res. 2013 Jul 11;5:355-67. doi: 10.2147/CEOR.S44060. Print 2013.

19.

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.

Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljanski J, Salaun-Martin C, Sapin H, Bruhn D, Mathieu C, Theodorakis M.

Diabetes Metab Syndr Obes. 2013 Apr 26;6:171-85. doi: 10.2147/DMSO.S41827. Print 2013.

20.

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study.

Matthaei S, Reaney M, Mathieu C, Ostenson CG, Krarup T, Guerci B, Kiljanski J, Petto H, Bruhn D, Theodorakis M.

Diabetes Ther. 2012 Nov;3(1):6. doi: 10.1007/s13300-012-0006-7. Epub 2012 Jun 20.

21.

Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes.

Hansen M, Nielsen AR, Vilsbøll T, Lund A, Krarup T, Knop FK, Vestergaard H.

Pancreas. 2012 Nov;41(8):1316-8. doi: 10.1097/MPA.0b013e31824d9b93.

PMID:
22647735
22.

Steroid-induced insulin resistance and impaired glucose tolerance are both associated with a progressive decline of incretin effect in first-degree relatives of patients with type 2 diabetes.

Jensen DH, Aaboe K, Henriksen JE, Vølund A, Holst JJ, Madsbad S, Krarup T.

Diabetologia. 2012 May;55(5):1406-16. doi: 10.1007/s00125-012-2459-7.

PMID:
22286551
23.

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.

Knop FK, Aaboe K, Vilsbøll T, Vølund A, Holst JJ, Krarup T, Madsbad S.

Diabetes Obes Metab. 2012 Jun;14(6):500-10. doi: 10.1111/j.1463-1326.2011.01549.x. Epub 2012 Jan 17.

PMID:
22171657
24.

Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing's syndrome?

Krarup T, Krarup T, Hagen C.

Diabetes Metab Res Rev. 2012 Mar;28(3):219-27. doi: 10.1002/dmrr.2262. Review.

PMID:
22162117
25.

Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function.

Kielgast U, Krarup T, Holst JJ, Madsbad S.

Diabetes Care. 2011 Jul;34(7):1463-8. doi: 10.2337/dc11-0096. Epub 2011 May 18.

26.

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.

Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S.

Diabetes Care. 2011 May;34 Suppl 2:S251-7. doi: 10.2337/dc11-s227. Review. No abstract available.

27.
28.

Glucagon-like peptide-2, but not glucose-dependent insulinotropic polypeptide, stimulates glucagon release in patients with type 1 diabetes.

Christensen M, Knop FK, Vilsbøll T, Aaboe K, Holst JJ, Madsbad S, Krarup T.

Regul Pept. 2010 Aug 9;163(1-3):96-101. doi: 10.1016/j.regpep.2010.05.004. Epub 2010 May 24.

PMID:
20580750
29.

Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis.

Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T.

Regul Pept. 2010 Sep 24;164(2-3):144-50. doi: 10.1016/j.regpep.2010.05.011. Epub 2010 Jun 2.

PMID:
20573586
30.

[Autoimmune hypophysitis].

Krarup T, Hagen C.

Ugeskr Laeger. 2010 Mar 15;172(11):875-80. Review. Danish.

PMID:
20412729
31.

[Autoimmune hypophysitis--a differential diagnosis to pituitary adenomas].

Krarup T, Hagen C.

Ugeskr Laeger. 2010 Mar 15;172(11):881-2. Danish.

PMID:
20403271
32.

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.

Aaboe K, Knop FK, Vilsbøll T, Deacon CF, Holst JJ, Madsbad S, Krarup T.

Diabetes Obes Metab. 2010 Apr;12(4):323-33. doi: 10.1111/j.1463-1326.2009.01167.x.

PMID:
20380653
33.

Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial.

Lundby Christensen L, Almdal T, Boesgaard T, Breum L, Dunn E, Gade-Rasmussen B, Gluud C, Hedetoft C, Jarloev A, Jensen T, Krarup T, Johansen LB, Lund SS, Madsbad S, Mathiesen E, Moelvig J, Nielsen F, Perrild H, Pedersen O, Roeder M, Sneppen SB, Snorgaard O, Tarnow L, Thorsteinsson B, Vaag A, Vestergaard H, Wetterslev J, Wiinberg N; CIMT Trial Group.

Diabetes Obes Metab. 2009 Apr;11(4):315-22. doi: 10.1111/j.1463-1326.2008.00959.x.

PMID:
19267709
34.

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.

Courrèges JP, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Bugáñová I, Madsbad S.

Diabet Med. 2008 Sep;25(9):1129-31. doi: 10.1111/j.1464-5491.2008.02484.x. No abstract available.

35.

KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Aaboe K, Knop FK, Vilsboll T, Vølund A, Simonsen U, Deacon CF, Madsbad S, Holst JJ, Krarup T.

J Clin Endocrinol Metab. 2009 Feb;94(2):603-8. doi: 10.1210/jc.2008-1731. Epub 2008 Dec 2.

PMID:
19050053
36.

Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes.

Højberg PV, Vilsbøll T, Zander M, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

Diabet Med. 2008 Nov;25(11):1268-75. doi: 10.1111/j.1464-5491.2008.02579.x.

PMID:
19046215
37.

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.

Højberg PV, Vilsbøll T, Rabøl R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S.

Diabetologia. 2009 Feb;52(2):199-207. doi: 10.1007/s00125-008-1195-5. Epub 2008 Nov 27.

PMID:
19037628
38.

[Cystectomy in Denmark 2001-2005].

Krarup T.

Ugeskr Laeger. 2008 Jun 16;170(25):2260; author reply 2261. Danish. No abstract available.

PMID:
18581651
39.

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.

Madsbad S, Krarup T, Deacon CF, Holst JJ.

Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):491-9. doi: 10.1097/MCO.0b013e328302f414. Review.

PMID:
18542012
40.

GLP-1: physiological effects and potential therapeutic applications.

Aaboe K, Krarup T, Madsbad S, Holst JJ.

Diabetes Obes Metab. 2008 Nov;10(11):994-1003. doi: 10.1111/j.1463-1326.2008.00853.x. Epub 2008 Apr 22. Review.

PMID:
18435775
41.

Glucagon-like peptide-1, glucose homeostasis and diabetes.

Holst JJ, Deacon CF, Vilsbøll T, Krarup T, Madsbad S.

Trends Mol Med. 2008 Apr;14(4):161-8. doi: 10.1016/j.molmed.2008.01.003. Epub 2008 Mar 18. Review.

PMID:
18353723
42.

Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes.

Højberg PV, Zander M, Vilsbøll T, Knop FK, Krarup T, Vølund A, Holst JJ, Madsbad S.

Diabetologia. 2008 Apr;51(4):632-40. doi: 10.1007/s00125-008-0943-x. Epub 2008 Feb 22.

PMID:
18292985
43.

[Treatment of invasive bladder cancer].

Walter S, Krarup T.

Ugeskr Laeger. 2008 Jan 21;170(4):213. Danish. No abstract available.

PMID:
18282448
44.

Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.

Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad S.

Diabet Med. 2008 Feb;25(2):152-6. doi: 10.1111/j.1464-5491.2007.02333.x. Epub 2008 Jan 14.

PMID:
18201212
45.

The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance.

Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Holst JJ, Krarup T.

Regul Pept. 2007 Dec 4;144(1-3):123-30. Epub 2007 Jul 13.

PMID:
17692937
46.

Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?

Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T.

Diabetes. 2007 Aug;56(8):1951-9. Epub 2007 May 18.

47.

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP, Verhoeven R, Bugánová I, Madsbad S.

Diabetes Care. 2007 Jun;30(6):1608-10. Epub 2007 Mar 19. No abstract available.

PMID:
17372153
48.
49.

Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution.

Knop FK, Vilsbøll T, Larsen S, Højberg PV, Vølund A, Madsbad S, Holst JJ, Krarup T.

Am J Physiol Endocrinol Metab. 2007 Jan;292(1):E324-30. Epub 2006 Sep 5.

50.

The elimination rates of intact GIP as well as its primary metabolite, GIP 3-42, are similar in type 2 diabetic patients and healthy subjects.

Vilsbøll T, Agersø H, Lauritsen T, Deacon CF, Aaboe K, Madsbad S, Krarup T, Holst JJ.

Regul Pept. 2006 Dec 10;137(3):168-72. Epub 2006 Aug 28.

PMID:
16934887

Supplemental Content

Loading ...
Support Center